Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study. by Parlato, Marianna et al.
Intensive Care Med (2018) 44:1061–1070
https://doi.org/10.1007/s00134-018-5228-3
ORIGINAL
Circulating biomarkers may be unable 
to detect infection at the early phase of sepsis 
in ICU patients: the CAPTAIN prospective 
multicenter cohort study
Marianna Parlato1 , François Philippart2,3, Alexandra Rouquette4,5, Virginie Moucadel6, Virginie Puchois1, 
Sophie Blein6, Jean‑Pierre Bedos7, Jean‑Luc Diehl8,9, Olfa Hamzaoui10, Djillali Annane11,12, Didier Journois5,13, 
Myriam Ben Boutieb4, Laurent Estève6, Catherine Fitting1, Jean‑Marc Treluyer5,14, Alexandre Pachot6, 
Minou Adib‑Conquy1, Jean‑Marc Cavaillon1, Benoît Misset2,15,16* and The Captain Study Group
© 2018 Springer‑Verlag GmbH Germany, part of Springer Nature and ESICM
Abstract 
Purpose: Sepsis and non‑septic systemic inflammatory response syndrome (SIRS) are the same syndromes, differing 
by their cause, sepsis being secondary to microbial infection. Microbiological tests are not enough to detect infection 
early. While more than 50 biomarkers have been proposed to detect infection, none have been repeatedly validated.
Aim: To assess the accuracy of circulating biomarkers to discriminate between sepsis and non‑septic SIRS.
Methods: The CAPTAIN study was a prospective observational multicenter cohort of 279 ICU patients with hypo‑ or 
hyperthermia and criteria of SIRS, included at the time the attending physician considered antimicrobial therapy. 
Investigators collected blood at inclusion to measure 29 plasma compounds and ten whole blood RNAs, and—for 
those patients included within working hours—14 leukocyte surface markers. Patients were classified as having sepsis 
or non‑septic SIRS blindly to the biomarkers results. We used the LASSO method as the technique of multivariate 
analysis, because of the large number of biomarkers.
Results: During the study period, 363 patients with SIRS were screened, 84 having exclusion criteria. Ninety‑one 
patients were classified as having non‑septic SIRS and 188 as having sepsis. Eight biomarkers had an area under the 
receiver operating curve (ROC‑AUC) over 0.6 with a 95% confidence interval over 0.5. LASSO regression identified 
CRP and HLA‑DRA mRNA as being repeatedly associated with sepsis, and no model performed better than CRP alone 
(ROC‑AUC 0.76 [0.68–0.84]).
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Introduction
The systemic inflammatory response syndrome (SIRS) is 
a generalized inflammatory response in organs remote 
to an initial insult. Infection is caused by the invasion of 
normally sterile tissue, fluid, or body cavity by a poten-
tially pathogenic microorganism [1]. When the insult 
causing SIRS is an infection, it is called sepsis [2]. Sepsis 
affects about 18 million people a year and its mortality is 
estimated between 35% and 55% [3].
When infection is due to bacteria or fungi, urgent anti-
microbial treatment is required to reduce mortality [4, 5]. 
Optimization of early antimicrobial agent requires one 
to confirm infection as soon as patients present clini-
cal severity, such as a high quick SOFA score or serum 
lactate levels [6]. As clinical information alone is rarely 
sufficient to detect sepsis, many biomarkers have been 
studied, but few were consistently associated with infec-
tion in this context [7]. The most studied biomarkers 
were procalcitonin (PCT) [8], C-reactive protein (CRP), 
soluble triggering receptor expressed on myeloid cell-1 
(sTREM1), neutrophil expression of the high-affinity 
immunoglobulin-Fc fragment receptor I (cluster of dif-
ferentiation 64, CD64) [9–11], interleukin-6 (IL-6), IL-1 
receptor antagonist (IL-1ra), pro-vasopressin (or copep-
tin), and pro-adrenomedullin (pro-ADM). CRP and PCT 
have been shown to help to decrease antibiotic use [8, 
12]. To improve the diagnostic accuracy of these bio-
markers, several [10, 13, 14] attempted to develop bio-
marker combinations but none have been repeatedly 
validated.
Discrepancies in the results of the published studies 
may be due to heterogeneity in infection locations, ini-
tial severity, pathogens, or populations studied [15]. A 
biomarker able to distinguish between sepsis and non-
septic SIRS would help in reducing use of antibiotics and 
searching for other causes of the patients’ vital dysfunc-
tions [15].
The aim of our study was to assess, in intensive care 
unit (ICU) patients with SIRS, the accuracy of individ-
ual or combined circulating biomarkers to discriminate 
between sepsis and non-septic SIRS. Our hypothesis 
was that, by studying a large panel of markers, it would 
be possible to obtain a predictive model which performs 




We set up the CAPTAIN study (Combined Approach for 
The eArly diagnosis of INfection in sepsis) as an obser-
vational multicenter prospective cohort of ICU patients 
with SIRS criteria [1], as soon as they were considered for 
antibiotic therapy. We designed and conducted this study 
according to STROBE (STrengthening the Reporting of 
OBservational studies in Epidemiology) guidelines [17] 
(electronic supplementary material (ESM) Table  1). The 
protocol was approved by the Comité de Protection des 
Personnes Ile de France XI (#2010-A00908-31-10056) on 
September 13, 2010 and registered as NCT01378169 on 
clinicaltrials.gov.
Setting
Patients were recruited in seven ICUs located in five 
hospitals in the Paris area. They were included from 
December 2011 to April 2013. Blood samples for bio-
markers were collected at inclusion. Blood samples 
for cell surface biomarkers were collected from those 
patients included when the research laboratory was 
open, owing to the necessity to perform extemporane-
ous analysis.
Participants
ICU patients with hypothermia (below 36.0 °C) or hyper-
thermia (over 38.0  °C) and at least another criterion of 
SIRS were eligible as soon as the physician considered 
antibiotic therapy. Other inclusion criteria were age over 
18  years, affiliation to the national health insurance sys-
tem, no treatment limitation, and no underlying immuno-
suppression (AIDS, immunosuppressive therapy, ongoing 
malignancy, organ or bone marrow transplant, or drug-
induced leukopenia). In a preliminary protocol, admission 
to the ICU was required to be less than 12 h (clinicaltri-
als.gov), but this criterion was abandoned before starting 
the study. Patient consent was collected if he/she was con-
scious and able to understand. The consent was waived in 
other situations.
Conclusions: The circulating biomarkers tested were found to discriminate poorly between sepsis and non‑septic 
SIRS, and no combination performed better than CRP alone.
Keywords: Sepsis, Cohort, CRP, HLA‑DRA mRNA
Take‑home message 
The circulating biomarkers tested were found to discriminate poorly 
between sepsis and non‑septic SIRS. No combination performed 
better than CRP alone.
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Outcome definition: sepsis and non‑septic SIRS diagnosis
Patients were classified as having sepsis in the presence of 
bacterial or fungal infection, or non-septic SIRS in other 
cases [1]. We called infections the diseases for which 
antibiotics were genuinely found to be useful. These dis-
eases are a subgroup of the diseases for which antibiot-
ics are recommended (i.e., suspicions of infections) and a 
larger group than the group of patients with bacteremia. 
For this reason, we had to refer to infections which are 
confirmed a posteriori, based on criteria which confirm 
infection as much as possible, either with or without pos-
itive cultures. A so-called gold standard for infection does 
not exist. In fact, as previously stated, the definition of 
infection and its causal link with SIRS required medical 
interpretation [18] and were based on Infectious Diseases 
Society of America (IDSA) guidelines. They were adjudi-
cated blindly to the studied biomarkers, by two investi-
gators (FP and BM). They reviewed the patients’ records, 
including clinical history, results of routine morpho-
logic, biological, or microbiological tests, and response 
to therapies during the days following inclusion. Among 
the biomarkers studied, CRP and PCT were not collected 
for routine purpose in two units (17.6% of the patients), 
were collected occasionally but were not considered 
as part of the diagnostic of sepsis in four units (71.7%), 
and were collected in routine and usual part of the sep-
sis diagnosis in one unit (10.8%). CRP and PCT were not 
provided to the two adjudicators. Strains were considered 
as infecting, colonizing, or contaminants. Infection could 
be considered as present despite the absence of a positive 
microbiological sample, e.g., in cases of abscess or pneu-
monia. When bacteremia was present, it was linked to 
the most probable anatomical focus of infection. Viruses 
were only searched for in case of influenza suspicion and 
were classified as non-septic SIRS. Disagreements on 
classification were resolved after discussion between the 
two adjudicators.
Study biomarkers
Fifty-three biomarkers were selected because they had 
been proposed in prior publications. Of these, 14 cell sur-
face biomarkers were assessed only for samples collected 
and delivered to the laboratory during open hours. Blood 
samples were collected in  PAXgene®, EDTA and heparin-
ized tubes and transferred to Institut Pasteur’s laboratory 
within 2 h after collection, in a cool bag. The methods of 
quantification were ELISA and multiplex analysis for 7 
and 22 plasma biomarkers, respectively, real-time poly-
merase chain reaction (RT-PCR) for 10 whole blood 
RNA biomarkers, and flow cytometry for 14 cell surface 
biomarkers (ESM Table  2). The analytic methods are 
reported in ESM Section  2.5. The kits used, the limits 
of quantification, and the primer and probe designs for 
mRNAs are reported on ESM Tables 3, 4, and 5.
Clinical and routine biological data
Demographics, reasons for ICU admission, underlying 
diseases, simplified acute severity score (SAPS 2) [19], 
physiological data, Sequential Organ Failure Assessment 
(SOFA) score [20], and length of organ failure supply 
were collected at admission to the ICU, at inclusion in 
the study, and over the ICU stay.
Data management and statistics
Sample size
The area under the receiver operating characteris-
tic curve (ROC-AUC) of PCT for sepsis diagnosis was 
reported to be 0.78 [95% CI 0.73–0.83] in 2007 [16]. We 
hypothesized that the ROC-AUC of the best combination 
tested in our population would reach 0.85. Three hun-
dred patients needed to be included (150 in each group, 
type I error risk = 0.05, power = 0.80, correlation between 
the two ROC-AUCs = 0.4) to find a significant difference 
between the biomarker combination ROC-AUC and the 
ROC-AUC of PCT alone [21] under this hypothesis. As 
we could not be sure that the ratio of sepsis to non-septic 
SIRS patients would be 1:1 and as we expected missing 
data, we decided to screen 360 patients.
Data analysis
A statistical analysis plan (SAP) was prepared prior to 
data collection in the protocol. It included the selection 
of biomarkers associated with sepsis in bivariate analy-
ses with a p value < 0.2, followed by a multivariate logis-
tic regression to identify the biomarkers independently 
linked with the outcome. This first analytical strategy 
identified CRP as the only biomarker being significantly 
linked with sepsis (data not shown). However, miss-
ing data were numerous and we decided to use a more 
powerful analytical strategy to handle  the large number 
of biomarkers (logistic LASSO regression) alongside with 
missing data (multiple imputations) (ESM 2.7.2.1) [22]. 
Data were described using median [IQR] and frequency 
(%). We used three imputation methods for values below 
the lower limit of quantification (LLoQ), over the upper 
limit of quantification (ULoQ), and for missing data. Col-
linearity among continuous markers was assessed using 
Spearman correlation coefficient. The ROC-AUC was 
used to evaluate diagnostic accuracy of each continuous 
marker in univariate analyses. Rubin’s rules [23] were 
applied to combine correlations, ROC-AUCs, and their 
95% associated confidence intervals over the imputed 




LASSO is a modelling method [22, 24] (ESM 2.7.3) used 
to select a subset of the strongest predictors associated 
with a given outcome, according to a shrinkage param-
eter λ. It includes the construction of multiple predictive 
train and test models by bootstrap, the determination 
and application of a λ value giving the best compromise 
between high ROC-AUC values and low optimism, and 
the selection of the biomarkers that are the most fre-
quently selected in the predictive models. Independ-
ent variables are entered altogether in the model, and 
a subset of them is selected as output. The number of 
selected variables depends on λ: the higher λ, the fewer 
variables selected. Optimism is observed when perfor-
mances of a predictive model are estimated for samples 
that were used to build this model. Model coefficients are 
optimized to fit as much of the data used to train it as 
possible. It is expected that the performance of a model 
applied to new data that were not used to train the model 
will be lower, but more representative of the performance 
one can expect in real life. Additional methodological 
and statistical details can be found in the ESM.
Results
Participants
A total of 363 patients were screened and 279 were 
included. Non-inclusions were due mostly to refusal of 
consent or to absence of an inclusion criterion (Fig. 1). A 
total of 188 were classified as sepsis and 91 as non-septic 
SIRS. The adjudicators similarly classified 239 patients 
(85.6%), and 40 (14.3%) were classified by consensus 
after initial disagreement. All patients had exploration of 
plasma circulating biomarkers and 110 (77 sepsis and 33 
non-septic SIRS patients) had exploration of cell surface 
biomarkers. These patients had a slightly higher severity 
at inclusion (SOFA score = 11 [9–14] versus 9 [9, 10]). 
While the number of inclusions was lower than expected 
in the non-septic SIRS group, we decided to assess the 
ROC-AUC of PCT, because it was the basis of our sample 
size calculation. The ROC-AUC of PCT was 0.55 [0.47–
0.62], which was lower than expected [16]. This made our 
sample size estimate excessive and we decided to stop 
including patients.
Inclusion occurred 0 [0–1]  days after ICU admission. 
Forty-two patients (15%, 34 sepsis and 8 non-septic SIRS) 
were included after day 2 (one patient was included on 
day 248). Patients’ characteristics at ICU admission and 
at study inclusion are shown in Tables 1 and 2. The SAPS 
2 score at ICU admission was 55 [50–61] in both groups. 
Temperature was higher and PaO2, serum lactate, and 
hematocrit were lower in sepsis than in non-septic SIRS 
patients. The causes of non-septic SIRS were mainly 
circulatory insufficiency or inflammatory states (ESM 
Table 7), and the anatomic locations of infection in sepsis 
patients were mainly lung and abdomen (ESM Table 8). 
The causal pathogens of these infections are provided in 
ESM Table 9. A combination of pathogens was found in 
46 (24%) and neither bacterium nor fungus was found in 
27 (14%) patients with sepsis, among whom 24 had lung 
and three had abdominal infections. The mortality of the 
two groups at the end of the hospital stay was similar 
(63/188 [33%] versus 28/91 [31%], p = 0.54). The ICU stay 
after inclusion and the hospital stay after ICU discharge 
were longer in the sepsis than in the non-septic SIRS 
patients (9 [4–22] versus 4 [2–11] days, p < 0.001, and 24 
[9–48] versus 13 [7–24] days, p < 0.001). 
Biomarkers
Univariate analyses
Missing data ranged from 11% to 16% for the 39 plasma 
and RNA biomarkers in 279 patients, and from 3% to 
54% for the 14 cell surface biomarkers available in 110 
patients (ESM Table  10). Most missing data were due 
to insufficient volume of the blood sample. Thirteen 
plasma and three RNA biomarkers were significantly 
different between sepsis and non-septic SIRS patients: 
CRP, suPAR, PSP, G-CSF, IL-6, IL-8, IP-10, MIP-1α, 
MIP-1β, MMP8, PCT, and S100A9 were higher, while 
MIF, RANTES, HLA DR mRNA, and CD74 mRNA were 
lower. Four cell surface biomarkers were significantly 
different between sepsis and non-septic SIRS patients: 
CD64-Neutrophil-MFI, and MFI intraTLR4 in CD56Dim 
were higher, while HLA-DR on CD14 high and low were 
lower (ESM Table 2).
Figure 2 describes the ROC-AUC of the 28 biomarkers 
treated as quantitative data and computed using each of 
the three imputation methods. The different imputation 
methods did not impact the results and only eight mark-
ers had a ROC-AUC above 0.6 and a 95% confidence 
lower limit above 0.5. These were CRP (ROC-AUC = 0.73 
[0.65–0.81]), HLA-DRA mRNA (0.65 [0.58–0.77]), pan-
creatic stone protein (PSP) (0.63 [0.54–0.71]), CD74 
mRNA (0.62 [0.53–0.72]), metalloproteinase 8 (MMP8) 
(0.62 [0.54–0.70]), suPAR (= 0.62 [0.53–0.71]), IL-6 (0.60 
[0.51–0.68]), and S100A9 (0.62 [0.50–0.67]).
LASSO statistics
Among the 12,500 predictive models computed, opti-
mism between train and test samples was close to 0 
for a λ between 0.1 and 0.16 (ESM Fig.  4). ROC-AUCs 
decreased slightly when λ increased from 0.1 to 0.16 
(ESM Fig. 5). We chose a λ = 0.1 because it allowed the 
best compromise between ROC-AUC and optimism. For 
λ = 0.1, CRP was selected in the LASSO logistic regres-
sion model in 95–99% of the 500 samples and HLA-
DRA mRNA was selected in 33–58% of the 500 samples, 
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depending on the imputation method. None of the other 
markers were selected in more than 30% of the samples 
(ESM Fig.  6). The mean train ROC-AUC of the model 
was 0.76 [0.68–0.84] while mean test ROC-AUC was 0.72 
[0.57–0.83], whatever the imputation method. The ROC-
AUCs of two previously published combinations [25, 26] 
are displayed in Table E6, and another one [10] could not 
be assessed because of an insufficient number of values 
for one of the parameters (PMN CD64 index).
Discussion
We assessed plasmatic and whole blood RNAs in a pro-
spective multicenter cohort of 279 ICU patients with 
criteria of SIRS, and assessed cell surface biomarkers in 
110 of these patients. Two-thirds of the patients were 
diagnosed as having sepsis and one-third as having non-
septic SIRS, blindly to the results of the biomarkers. The 
ROC-AUC of PCT, which we had used as the reference 
value to calculate the sample size, was much lower in our 
series (median 0.55) than in Tang et  al’s meta-analysis 
(mean 0.78) [16]. This discrepancy may be due to dif-
ferences in gold- standard in the individual studies [27] 
Patients screened (SIRS), n=363
Patients not included, n = 84
- absence of consent: n = 7
- inclusion criterion missing: n = 50
o absence of hypo- or hyperthermia: n= 34
oother: n = 16
- non-inclusion criterion present:
o immunosuppression: n= 8
o legal protection: n = 8
oalready on antibiotics: n = 8
oalready included in the same study: n= 3
Patients included, n= 279
Sepsis, n = 188 Non-septic SIRS, n = 91
With cell surface 
biomarkers
n = 77
Without cell surface 
biomarkers
n = 58
Without cell surface 
biomarkers
n = 111





and to the populations studied. In fact, as procalcitonin 
is a marker of severity [28], high ROC-AUC may be 
due to lower severity [27] or mortality [27, 29] in non-
septic SIRS patients from previous series, secondary to 
differences in inclusion criteria. We did not expect this 
result, which made our sample size estimate inadequate 
for this population. Therefore, we decided to stop inclu-
sions as initially planned. The biomarker with the highest 
observed ROC-AUC to discriminate between sepsis and 
non-septic SIRS was CRP, and no combination of bio-
markers was found to improve its diagnostic accuracy.
Sepsis is a life-threatening organ dysfunction caused 
by a dysregulated host response to infection [2]. In case 
of infection, early antibiotic therapy is associated with a 
reduction of mortality [4], while in the absence of infec-
tion the search for an alternate diagnosis must be aggres-
sive to initiate appropriate therapy [30, 31]. This justifies 
searching discriminatory biomarkers available in routine 
use. Such biomarkers have been studied in prior stud-
ies. As a gold standard definition of infection does not 
exist, the groups may be heterogeneous across studies. 
We chose to include patients with SIRS, for whom the 
attending clinician was suspecting infection and consid-
ering antibiotic therapy. To initiate early therapy, such 
an a priori suspicion of sepsis was in accordance with 
the recommendations of the Surviving Sepsis Campaign 
[5]. While our study was not designed to evaluate com-
pliance with these guidelines, differences in individual 
practices may have influenced the time of inclusion. We 
classified patients a posteriori using two blind adjudica-
tors, and used conventional definitions [10, 30, 32]. Our 
series comprises 67% infected patients. Pneumonia was 
the predominant location of infection and the strains 
responsible for infections were predominantly Gram-
negative bacteria, consistent with epidemiology in ICUs 
[33, 34]. Unlike prior series [10, 14], as measured with 
Table 1 Characteristics of the patients at ICU admission
Sepsis N = 188 Non‑septic SIRS N = 91 p value Missing values n (%)
Age (years) 64.7 [52.5–77.7] 65.5 [51.0–78.8] 0.98 0
Male sex, n (%) 124 (66.0) 55 (60.4) 0.38 0
SAPS 2 score 55 [50–61] 55 [50–61] 0.81 0
Reason for admission to ICU, n (%) 0.31 0
 Acute respiratory failure 67 (35.6) 30 (33.0)
 Septic shock 25 (13.3) 0 (0.0)
 Hypovolemic shock 7 (3.7) 3 (3.3)
 Other shock 8 (4.3) 10 (10.1)
 Convulsive state 9 (4.8) 8 (8.8)
 Coma 23 (12.2) 16 (17.6)
 Surgical abdomen 7 (3.7) 2 (2.2)
 Other 42 (22.3) 22 (24.2)
Location of origin, n (%) 0.43 0
 Emergency department 67 (35.6) 29 (31.9)
 Direct admission 53 (28.2) 37 (70.7)
 Ward 47 (25.0) 18 (19.8)
 Operating room 12 (6.4) 4 (4.4)
 Other ICU 9 (4.8) 3 (3.3)
Underlying disease, n (%) 2 (0.7)
 Chronic obstructive pulmonary disease 38 (20.2) 12 (13.2) 0.25
 Cardiac insufficiency 21 (11.2) 11 (12.1) 0.85
 Diabetes 40 (21.3) 17 (18.7) 0.88
 Chronic renal insufficiency 15 (8.0) 9 (9.9) 0.38
 Cancer 29 (15.4) 8 (8.8) 0.15
 Hematological malignancy 2 (1.0) 0 (0.0) 1.00
 Chronic liver disease 14 (7.4) 6 (6.6) 0.38
McCabe score, n (%) 0.18 3 (1.1)
 1—No fatal disease 143 (76.1) 75 (82.4)
 2—Estimated vital prognosis less than 5 years 42 (22.3) 15 (16.5)
 3—Estimated vital prognosis less than 1 year 1 (0.5) 0 (0.0)
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SAPS 2 score, our two groups had similar severity. This 
may result from our using the time when the physician 
was about to initiate antibiotic therapy among the inclu-
sion criteria. The ICU mortality of our patients was high 
(31% and 33%) and consistent with their SAPS 2 scores 
at ICU admission [19]. Similarly, the SOFA score, which 
has become part of the sepsis description [2], was high 
(9 [8–10)] and similar in our two groups, allowing us to 
discard severity as a confounding factor. We observed 
differences between the two groups: the high preva-
lence of hypoxemia in our sepsis group may be due to 
the frequency of pneumonia [33]; higher serum lactate—
a marker of cellular hypoxia—and lower hematocrit in 
non-septic SIRS patients may result from the frequency 
of circulatory dysfunction and is consistent with the role 
of tissue hypoxia, ischemia, and reperfusion in the patho-
physiology of SIRS [35]. Lastly, sepsis patients had longer 
ICU and hospital stays than non-septic SIRS patients. 
This may reflect that source control [5] and resolution of 
infection are slower to achieve than resolution of events 
such as ischemia–reperfusion syndrome.
An important result of our study is that the circulat-
ing biomarkers did not differ substantially whether the 
stimulus for clinical inflammation was microbial or not. 
This may relate to the similarity of the mediator cascade 
and cell interaction profiles, whether the involved stimuli 
are pathogen-associated molecular patterns (PAMPs) 
or danger-associated molecular patterns (DAMPs) [36]. 
Considering the large amount of literature promoting 
the use of PCT to guide antibiotic prescription [15], our 
results were unexpected. This may have been due to the 
similar level of severity of our two groups and the strong 
link between PCT and mortality, as reported in a recent 
large international cohort [28]. The good performance 
of CRP relative to other markers is consistent with pre-
vious studies [9, 11, 13] and with the fact that CRP use 
was found to successfully decrease the duration of anti-
biotic therapy [12]. In two important studies, it was 
not assessed [10] or was used as part of the criteria of 
infection [14] precluding its assessment as a diagnostic 
marker. Also, the fact that we could not improve the diag-
nostic accuracy of CRP with a combination of biomarkers 
is consistent with one prior study [11], while two stud-
ies concluding differently either addressed distinction 
between bacterial and viral infections [13] or were not 
reproduced [25, 26] (ESM Table 11).
Table 2 Clinical and biological characteristics of the patients at study inclusion
 Characteristics Sepsis N = 188 Non‑septic SIRS N = 91 p value Missing values n (%)
n = 188 n = 91
Time from ICU admission to inclusion (days) 0 [0–1] 0 [0–1] 0.05 0
Clinical data
 Temperature (°C) 38.7 [38.2–39.3] 38.6 [36.0–39.0] 0.03 0
 Respiratory rate (breaths/min) 27 [23–34] 26 [21–32] 0.19 15 (3.6)
 Heart rate (beats/min) 117 [100–132] 112 [97–132] 0.42 10 (3.7)
 Mean arterial pressure (mmHg) 67.0 [55.5–84.0] 70.0 [58.5–83.5] 0.46 3 (1.1)
 Urine output (mL/24 h) 1250 [700–1970] 1110 [600–2000] 0.64 14 (5.2)
Biological data
 PaO2 (mmHg) 87 [70–114] 98 [77–134] 0.02 14 (5.2)
 FiO2 (%) 40 [30–60] 45 [30–60] 0.35 14 (5.2)
 PaCO2 (mmHg) 40 [34–47] 40 [34–45] 0.44 14 (5.2)
 Serum lactate (meq/L) 1.8 [1.2–2.5] 2.1 [1.4–5.3] 0.03 66 (24.5)
 Serum creatinine (mg/L) 11 [7–22] 13 [8–22] 0.13 10 (3.7)
 Blood leukocytes (×109/mL) 12.7 [9.2–18.6] 13.6 [9.1–17.0] 0.92 10 (3.7)
 Blood platelets (×109/L) 198 [122–287] 196 [126–269] 0.86 12 (4.5)
 Hematocrit (%) 31.0 [27.8–37.4] 36.0 [29.6–41.6] 0.001 15 (5.6)
 SOFA score 9 [8–10] 9 [9, 10] 0.06 14 (5.2)
Organ supply and specific drugs
 Mechanical ventilation, n (%) 142 (77.6) 66 (72.5) 0.12 11 (4.1)
 Non‑invasive mechanical ventilation, n (%) 19 (10.4) 11 (12.1) 0.56 11 (4.1)
 Vasopressor use (epinephrin or norepinephrin), n (%) 74 (40.9) 27 (30.7) 0.10 10 (3.6)
 Hemodialysis, n (%) 13 (7.2) 8 (9.1) 0.40 10 (3.6)
 Antibiotic use, n (%) 158 (87.3) 59 (67.0) 0.0001 10 (3.6)
 Steroids for suspected septic shock, n (%) 18 (9.9) 5 (5.7) 0.30 10 (3.6)
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Our study has several limitations. First, many eligi-
ble patients may not have been included, particularly 
because inclusion outside working hours of the research 
laboratory was discouraged. This may reduce generali-
zation of our results. Second, despite CRP and PCT not 
being provided to the adjudicators, the interpretations of 
the physicians in charge of some patients could be based 
in part on these results and were visible in the patients’ 
records and may have influenced the decisions of the 
adjudicators. Third, the dispersion of the ROC-AUC of 
most markers was large, secondary to the relatively small 
sample size. This sample size is, however, in the higher 
range of the studies which established the ROC-AUC of 
PCT [16] and served as a basis for our sample size calcu-
lation. Fourth, we could assess cell surface biomarkers in 
only 40% of our patients, because the cells require imme-
diate treatment in the research laboratory, i.e., during 
regular working hours. This was due to the fact we had 
planned to include patients independently of the hours 
of symptoms occurrence, to favor external validity. Also, 
we obtained a substantial amount of missing data for 
these cell surface biomarkers, mainly because of a short-
age of blood sample volume. This reduces the validity of 
our findings regarding these biomarkers. For example, 
the positive results we observed in our first 28 patients 
[37] for CD24 on neutrophils were not confirmed in the 
present whole cohort. Fifth, we had to adjust our initial 
statistical plan analysis, from a conventional approach 
with multivariate regression to the LASSO technique, 
after we observed the large number of missing values. 
Last, as the study was only conducted in ICUs in the 
Paris area, the external validity in other countries or 
smaller hospitals may be decreased.
Conclusion
In this prospective multicenter cohort, addressing most 
circulating biomarkers previously tested in the setting 
of sepsis, and using the LASSO biostatistical method, 
we found that these biomarkers poorly discriminated 
sepsis from non-septic SIRS patients and that no one 
biomarker, alone or in combination, performed better 
than CRP alone. Because cell surface biomarkers were 
collected in only 40% of the patients, the validity of our 
results is weaker for these biomarkers.
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